Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845717 | 1.00 | F10 (0.48) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL541807 | 0.84 | CALML3 (0.59) | MAOBMAOACALML3S1PR5 | |
| SCHEMBL541806 | 0.84 | CALML3 (0.59) | MAOBMAOACALML3S1PR5 | |
| SCHEMBL2837784 | 0.82 | GRM2 (0.47) | F10CALML3S1PR5 | |
| SCHEMBL9611100 | 0.82 | GRM2 (0.49) | CALML3S1PR5 | |
| SCHEMBL17769261 | 0.82 | GRM2 (0.47) | CALML3S1PR5 | |
| SCHEMBL17769259 | 0.82 | GRM2 (0.47) | CALML3S1PR5 | |
| SCHEMBL2838615 | 0.81 | F10 (0.56) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL2838621 | 0.81 | F10 (0.56) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL17769268 | 0.81 | GRM2 (0.47) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-1931684-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007017828-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | F10 3355/4885MAOB 1605/4885MAOA 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.